Results 61 to 70 of about 2,519,772 (150)

Obeticholic acid improves fetal bile acid profile in a mouse model of gestational hypercholanemia. [PDF]

, 2020
Intrahepatic cholestasis of pregnancy (ICP) is characterized by elevated maternal circulating bile acid levels and associated dyslipidemia. ICP leads to accumulation of bile acids in the fetal compartment, and the elevated bile acid concentrations are ...
Marchesi, Julian R, Williamson, Catherine, Marschall, Hanns-Ulrich,, McIlvride, Saraid, Shapiro, David, Marschall, H.-U., Wahlström, Annika, Ovadia, C., Jansen, E., Jansen, Eugene, Adorini, Luciano, McIlvride, S., McDonald, Julie A K, McDonald, Julie A. K., Pataia, Vanessa, Wahlström, Annika,, Pataia, V., Wahlström, A., Marchesi, J.R., Adorini, L., Marschall, Hanns-Ulrich, Marchesi, Julian R., Papacleovoulou, G., Shapiro, D., Ovadia, Caroline, Papacleovoulou, Georgia, McDonald, J.A.K., Williamson, C.   +27 more
core   +1 more source

Iron‐Sulfur Cluster Targeting: A Novel Perspective for Treating Alcohol‐Related Lipid Metabolic Diseases

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 9, September 2026.
Alcohol metabolism induces structural instability of iron‐sulfur clusters through ROS‐mediated oxidative damage and direct covalent modification of acetaldehyde. The iron‐sulfur cluster deficiency drives metabolic reprogramming by inactivating aconitase, accumulating succinate, and impairing tRNA thiolation, thereby promoting hepatic steatosis ...
Li Xu, Zhenyang Xu, Chenli Su, Yanqian Zhao, Linjing Qiang, Xiayong Jing, Yuxiang Sun   +6 more
wiley   +1 more source

Metabolic Syndrome: From Mechanisms to Therapeutic Interventions

MedComm, Volume 7, Issue 9, September 2026.
A comprehensive overview of molecular mechanisms delves into the potential disease mechanisms of metabolic syndrome, including complex mechanisms such as insulin resistance, chronic low‐grade inflammation, oxidative stress, and epigenetic modifications, and how these mechanisms contribute to the development of metabolic syndrome. Here, the relationship
Mengyao Yan, Qian Xiang
wiley   +1 more source

Farnesoid X receptor prevents hyperuricemia via activating ATP‐binding cassette subfamily G member 2

Rheumatology &Autoimmunity, Volume 6, Issue 3, Page 169-176, September 2026.
Farnesoid X receptor (FXR) activation reduces serum uric acid levels by upregulating the intestinal urate transporter ATP‐binding cassette subfamily G member 2 (ABCG2). These findings uncover a novel metabolic pathway for urate excretion and suggest that FXR agonists (e.g., obeticholic acid), represent a promising therapeutic strategy for the treatment
Rui Li, Guo Tang, Ye Yu, Guang‐Liang Chen, Liangjing Lu, Juan Wang   +5 more
wiley   +1 more source

Cost‐Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in the United States

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8378-8389, September 2026.
ABSTRACT Aims The approval of new pharmacotherapies for metabolic dysfunction‐associated steatohepatitis (MASH) presents a critical need for value assessment. We evaluated the cost‐effectiveness of resmetirom, semaglutide and tirzepatide for U.S. adults with MASH and F2–F3 fibrosis.
Ali A. Abdeen, Turgay Ayer, Aanan Biswas, Chase J. Wehrle, Sobia N. Laique, Ali Aminian   +5 more
wiley   +1 more source

Bioequivalence and Pharmacokinetic Profiles of Generic and Branded Obeticholic Acid in Healthy Chinese Subjects Under Fasting and Fed Conditions

Drug Design, Development and Therapy, 2021
Meng-Na Wang,1,* Hai-Tao Yu,2,* Ya-Qian Li,1 Yun Zeng,1 Shuang Yang,3 Guo-Ping Yang,1,3– 6 Qi Pei,6 Jie Huang1,3 1Center for Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, People’s ...
Wang MN, Yu HT, Li YQ, Zeng Y, Yang S, Yang GP, Pei Q, Huang J   +7 more
doaj  

Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction‐Associated Steatotic Liver Disease

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8277-8287, September 2026.
ABSTRACT Aims Treatment options for metabolic dysfunction‐associated steatotic liver disease (MASLD) are limited. While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors improve cardiovascular outcomes, comparative effectiveness on liver‐related outcomes remains unclear.
Gregor A. Maier, Ramon A. Hofmann, Michael Roden, Wolfgang Rathmann, Oliver Kuss   +4 more
wiley   +1 more source

Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases

Frontiers in Pharmacology, 2020
Cardiometabolic diseases are characterized as a combination of multiple risk factors for cardiovascular disease (CVD) and metabolic diseases including diabetes mellitus and dyslipidemia.
Chao Li, Jie Yang, Yu Wang, Yingzi Qi, Wenqing Yang, Yunlun Li, Yunlun Li   +6 more
doaj   +1 more source

Treatment Goals for Primary Biliary Cholangitis, an Australian Perspective

Journal of Gastroenterology and Hepatology, Volume 41, Issue 9, Page 2623-2638, September 2026.
ABSTRACT Primary biliary cholangitis (PBC) is an autoimmune liver disease that targets the small intrahepatic bile ducts with diagnosis based on elevated serum alkaline phosphatase (ALP) levels and the presence of anti‐mitochondrial antibodies. Untreated, it may run a progressive course to cirrhosis and hepatic decompensation, at which point liver ...
Simone I. Strasser, Alexander J. Thompson, Rohit Gupta, John Lubel, Janine French, Beverly Sacks, Martin Weltman   +6 more
wiley   +1 more source

MAFLD/MASLD: Past, Present, and Future

Journal of Gastroenterology and Hepatology, Volume 41, Issue 9, Page 2882-2892, September 2026.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD), also known as nonalcoholic fatty liver disease and metabolic dysfunction‐associated fatty liver disease, affects more than 30% of the global adult population and has become one of the leading causes of cirrhosis and hepatocellular carcinoma.
Vincent Wai‐Sun Wong
wiley   +1 more source